Movement Disorders

Neurology News Network for the week of January 5, 2019.

The position statement’s author noted that a lack of specificity in laws and inconsistencies in protocols has led to confusion surrounding brain death in several high-profile cases.

The program’s director spoke about its genesis and evolution into a more widespread initiative which has helped improve next-generation genome sequencing.

The FDA notice stated that these discontinuations are the result of a business decision by manufacturer GlaxoSmithKline.

The associate professor of neurology and the director of clinical trials at the University of Florida’s Center for Movement Disorders and Neurorestoration spoke about what’s being developed in the Parkinson disease pipeline.

The associate professor of neurology and the director of clinical trials at the University of Florida’s Center for Movement Disorders and Neurorestoration spoke about addressing the complex relationship between caregivers in treating tardive dyskinesia.

The approval marks the first and only of its kind, with the treatment anticipated to be commercially available by prescription in the US sometime in Q1 of 2019.

The approval adds medication-refractory tremor from Parkinson disease to the current indication for incisionless, focused ultrasound thalamotomy.

The results of the study found that those taking IRL790 had a mean reduction of 8.2% in dyskinesia scores compared to placebo.

After failing to show motor symptom improvement in patients with Huntington disease in several clinical trials, pridopidine may have hit the end of its developmental road.

Growing enthusiasm in the Parkinson disease research community largely centers on advances in understanding the genetic underpinnings of the disease.

The progression of Parkinson disease and response to medication varies widely across individuals, which can make the prediction of disease course challenging.

Long-term consumption of fruits and vegetables may be associated with a lower risk of memory loss over time in men.

Neurology News Network for the week of December 1, 2018.

The director of Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital discussed this pipeline of therapies and the enhancement of the clinical understanding of the disease.

Does the atypical antipsychotic clozapine carry high risk for the development of drug-induced parkinsonism? What are DSM-5 criteria for the diagnosis of neuroleptic-induced parkinsonism? These questions and more in our quiz.

Neurology News Network for the week of November 17, 2018.

Therapies designed to treat neurologic conditions have made up 25% of the submissions to the FDA for a Regenerative Medicine Advanced Therapy designation.

The product was being marketed for conditions including Alzheimer disease, fibromyalgia, spinal cord injury, multiple sclerosis, muscular dystrophy, Parkinson disease, and peripheral neuropathy, among others.

The professor emeritus of psychiatry at the University of Pennsylvania’s Perelman School of Medicine discussed the imperative need for physicians to recognize tardive dyskinesia.

The professor of neurology at Virginia Commonwealth University discussed all the progress that’s been made in the space and shared her thoughts on the advances.

The professor emeritus of psychiatry at the University of Pennsylvania’s Perelman School of Medicine spoke about the condition and the available therapies, as well as some of the needs that remain unmet.

The associate professor of neurology and neuroscience at Weill Cornell Medicine spoke about the history of cell therapies for Parkinson disease and how it’s informing current work.

The Pediatric Movement Disorders Neurologist at UT Southwestern recommends that when encountering a patient with a movement disorder to organize your thought process in 3 steps.

The associate professor of neurology and neuroscience at Weill Cornell Medicine discussed this work, and what she and her colleagues believe could be addressed by a successful effort.